Nuvation Bio [NUVB] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Nuvation Bio Inc. wins in 6 metrics, Zymeworks Inc. wins in 11 metrics, with 0 ties. Zymeworks Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nuvation Bio Inc. | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 3.79 | N/A |
| Price-to-Book Ratio | 5.81 | 7.32 | Nuvation Bio Inc. |
| Debt-to-Equity Ratio | 21.90 | 6.80 | Zymeworks Inc. |
| PEG Ratio | -35.31 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | -6.23 | -20.40 | Nuvation Bio Inc. |
| Profit Margin (TTM) | 85.22% | -76.56% | Nuvation Bio Inc. |
| Operating Margin (TTM) | -81.30% | -1,755.55% | Nuvation Bio Inc. |
| Return on Equity | -53.18% | -26.72% | Zymeworks Inc. |
| Return on Assets (TTM) | -23.46% | -14.29% | Zymeworks Inc. |
| Free Cash Flow (TTM) | $-181.78M | $-35.36M | Zymeworks Inc. |
| 1-Year Return | 125.47% | 119.86% | Nuvation Bio Inc. |
| Price-to-Sales Ratio (TTM) | 28.30 | 18.46 | Zymeworks Inc. |
| Enterprise Value | $1.32B | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | 20.94 | 16.33 | Zymeworks Inc. |
| Gross Profit Margin (TTM) | 96.94% | N/A | N/A |
| Revenue per Share (TTM) | $0 | $1 | Zymeworks Inc. |
| Earnings per Share (Diluted) | $-0.60 | $-1.08 | Nuvation Bio Inc. |
| Beta (Stock Volatility) | 1.61 | 1.20 | Zymeworks Inc. |
| Short % of Float | 23.23% | 8.16% | Zymeworks Inc. |
Nuvation Bio Inc. vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nuvation Bio Inc. | -3.67% | -0.42% | 7.03% | 8.26% | -43.61% | -44.99% |
| Zymeworks Inc. | 1.00% | -1.77% | -9.07% | -0.41% | -7.13% | -8.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nuvation Bio Inc. | 125.47% | 179.53% | -60.98% | -51.96% | -51.96% | -51.96% |
| Zymeworks Inc. | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
Performance & Financial Health Analysis: Nuvation Bio Inc. vs Zymeworks Inc.
| Metric | NUVB | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $1.75B | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,882,977 | 626,460 |
| 90 Day Avg. Volume | 3,312,782 | 729,503 |
| Last Close | $4.72 | $24.35 |
| 52 Week Range | $1.57 - $9.75 | $11.51 - $29.75 |
| % from 52W High | -51.59% | -18.15% |
| All-Time High | $15.23 (May 24, 2021) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -69.01% | -58.75% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 6.33% | -0.92% |
| Quarterly Earnings Growth | 6.33% | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.85% | -0.77% |
| Operating Margin (TTM) | -0.81% | -17.56% |
| Return on Equity (TTM) | -0.53% | -0.27% |
| Debt to Equity (MRQ) | 21.90 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.88 | $3.60 |
| Cash per Share (MRQ) | $1.52 | $3.10 |
| Operating Cash Flow (TTM) | $-173,427,008 | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $-115,776,248 | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nuvation Bio Inc. vs Zymeworks Inc.
| Metric | NUVB (Apr 24, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 3.79 |
| Forward P/E | -35.31 | 33.43 |
| PEG Ratio | -35.31 | 0.05 |
| Price to Sales (TTM) | 28.30 | 18.46 |
| Price to Book (MRQ) | 5.81 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $1.75B | $1.96B |
| Enterprise Value | $1.32B | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 20.94 | 16.33 |
| Enterprise to EBITDA | -6.23 | -20.40 |
| Risk & Other Metrics | ||
| Beta | 1.61 | 1.20 |
| Book Value per Share (MRQ) | $0.88 | $3.60 |
Financial Statements Comparison: Nuvation Bio Inc. vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | NUVB (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 62.90M | 105.97M |
| Cost of Goods Sold | 9.30M | N/A |
| COGS % of Revenue | 14.8% | 0.0% |
| Gross Profit | 53.60M | N/A |
| Gross Margin | 85.2% | 0.0% |
| Research & Development | 115.11M | 137.00M |
| Operating Income (EBIT) | -213.06M | -92.54M |
| Operating Margin | -338.7% | -87.3% |
| EBITDA | -188.37M | -80.82M |
| EBITDA Margin | -299.5% | -76.3% |
| Pre-Tax Income | -204.63M | -79.75M |
| Pre-Tax Income % of Revenue | -325.3% | -75.3% |
| Income Tax | 0 | 1.38M |
| Income Tax % of Revenue | 0.0% | 1.3% |
| Net Income (Profit) | -204.63M | -81.13M |
| Profit Margin | -325.3% | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | NUVB (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 164.09M | 41.16M |
| Total Current Assets | 571.52M | 248.77M |
| Total Current Assets % of Revenue | 908.6% | 234.8% |
| Total Current Liabilities | 82.23M | 42.32M |
| Total Current Liabilities % of Revenue | 130.7% | 39.9% |
| Long-Term Debt | 49.75M | 14.80M |
| Long-Term Debt % of Revenue | 79.1% | 14.0% |
| Total Shareholders Equity | 305.72M | 268.50M |
| Retained Earnings | -1.12B | -953.16M |
| Retained Earnings % of Revenue | -1,773.2% | -899.5% |
| Property, Plant & Equipment | 3.92M | 29.56M |
Cash Flow Statement Comparison
| Metric | NUVB (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | -175.98M | -40.00M |
| Operating Cash Flow % of Revenue | -279.8% | -37.7% |
| Capital Expenditures | -354,000 | -1.52M |
| Free Cash Flow | -181.78M | -35.36M |
| FCF Margin | -289.0% | -33.4% |
| Debt Repayment | -11.90M | N/A |
| Common Stock Repurchase | N/A | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | NUVB | ZYME |
|---|---|---|
| Shares Short | 48.73M | 4.08M |
| Short Ratio | 9.62 | 5.42 |
| Short % of Float | 23.23% | 8.16% |
| Shares Outstanding | 346.50M | 75.19M |
| Float Shares | 237.04M | 72.80M |
| % Held by Insiders | 18.67% | 1.26% |
| % Held by Institutions | 62.24% | 98.45% |
| % Held by Public | 19.09% | 0.29% |
Dividend Analysis & Yield Comparison: Nuvation Bio Inc. vs Zymeworks Inc.
| Metric | NUVB | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |